Floriano Amimo1,2, Ben Lambert3, Anthony Magit4, Masahiro Hashizume5. 1. Department of Global Health Policy, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan. florianoamimo@gmail.com. 2. Faculty of Medicine, Eduardo Mondlane University, Maputo, Mozambique. florianoamimo@gmail.com. 3. MRC Centre for Global Infectious Disease Analysis, School of Public Health, Imperial College London, London, W2 1PG, UK. 4. Human Research Protection Program, University of California San Diego School of Medicine, San Diego, California, USA. 5. Department of Global Health Policy, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan.
Abstract
BACKGROUND: The ongoing pandemic of coronavirus disease 2019 (COVID-19) has the potential to reverse progress towards global targets. This study examines the risks that the COVID-19 pandemic poses to equitable access to essential medicines and vaccines (EMV) for universal health coverage in Africa. METHODS: We searched medical databases and grey literature up to 2 October 2020 for studies reporting data on prospective pathways and innovative strategies relevant for the assessment and management of the emerging risks in accessibility, safety, quality, and affordability of EMV in the context of the COVID-19 pandemic. We used the resulting pool of evidence to support our analysis and to draw policy recommendations to mitigate the emerging risks and improve preparedness for future crises. RESULTS: Of the 310 records screened, 134 were included in the analysis. We found that the disruption of the international system affects more immediately the capability of low- and middle-income countries to acquire the basket of EMV. The COVID-19 pandemic may facilitate dishonesty and fraud, increasing the propensity of patients to take substandard and falsified drugs. Strategic regional cooperation in the form of joint tenders and contract awarding, joint price negotiation and supplier selection, as well as joint market research, monitoring, and evaluation could improve the supply, affordability, quality, and safety of EMV. Sustainable health financing along with international technology transfer and substantial investment in research and development are needed to minimize the vulnerability of African countries arising from their dependence on imported EMV. To ensure equitable access, community-based strategies such as mobile clinics as well as fees exemptions for vulnerable and under-served segments of society might need to be considered. Strategies such as task delegation and telephone triage could help reduce physician workload. This coupled with payments of risk allowance to frontline healthcare workers and health-literate healthcare organization might improve the appropriate use of EMV. CONCLUSIONS: Innovative and sustainable strategies informed by comparative risk assessment are increasingly needed to ensure that local economic, social, demographic, and epidemiological risks and potentials are accounted for in the national COVID-19 responses.
BACKGROUND: The ongoing pandemic of coronavirus disease 2019 (COVID-19) has the potential to reverse progress towards global targets. This study examines the risks that the COVID-19 pandemic poses to equitable access to essential medicines and vaccines (EMV) for universal health coverage in Africa. METHODS: We searched medical databases and grey literature up to 2 October 2020 for studies reporting data on prospective pathways and innovative strategies relevant for the assessment and management of the emerging risks in accessibility, safety, quality, and affordability of EMV in the context of the COVID-19 pandemic. We used the resulting pool of evidence to support our analysis and to draw policy recommendations to mitigate the emerging risks and improve preparedness for future crises. RESULTS: Of the 310 records screened, 134 were included in the analysis. We found that the disruption of the international system affects more immediately the capability of low- and middle-income countries to acquire the basket of EMV. The COVID-19 pandemic may facilitate dishonesty and fraud, increasing the propensity of patients to take substandard and falsified drugs. Strategic regional cooperation in the form of joint tenders and contract awarding, joint price negotiation and supplier selection, as well as joint market research, monitoring, and evaluation could improve the supply, affordability, quality, and safety of EMV. Sustainable health financing along with international technology transfer and substantial investment in research and development are needed to minimize the vulnerability of African countries arising from their dependence on imported EMV. To ensure equitable access, community-based strategies such as mobile clinics as well as fees exemptions for vulnerable and under-served segments of society might need to be considered. Strategies such as task delegation and telephone triage could help reduce physician workload. This coupled with payments of risk allowance to frontline healthcare workers and health-literate healthcare organization might improve the appropriate use of EMV. CONCLUSIONS: Innovative and sustainable strategies informed by comparative risk assessment are increasingly needed to ensure that local economic, social, demographic, and epidemiological risks and potentials are accounted for in the national COVID-19 responses.
Entities:
Keywords:
Africa; COVID-19; Essential medicines; Health policy; Health systems; SARS-CoV-2; Universal health coverage; Vaccines
Authors: Veronika J Wirtz; Hans V Hogerzeil; Andrew L Gray; Maryam Bigdeli; Cornelis P de Joncheere; Margaret A Ewen; Martha Gyansa-Lutterodt; Sun Jing; Vera L Luiza; Regina M Mbindyo; Helene Möller; Corrina Moucheraud; Bernard Pécoul; Lembit Rägo; Arash Rashidian; Dennis Ross-Degnan; Peter N Stephens; Yot Teerawattananon; Ellen F M 't Hoen; Anita K Wagner; Prashant Yadav; Michael R Reich Journal: Lancet Date: 2016-11-08 Impact factor: 79.321
Authors: Ellie Sherrard-Smith; Alexandra B Hogan; Arran Hamlet; Oliver J Watson; Charlie Whittaker; Peter Winskill; Fatima Ali; Audu B Mohammad; Perpetua Uhomoibhi; Ibrahim Maikore; Nnenna Ogbulafor; Jamilu Nikau; Mara D Kont; Joseph D Challenger; Robert Verity; Ben Lambert; Matthew Cairns; Bhargavi Rao; Marc Baguelin; Lilith K Whittles; John A Lees; Sangeeta Bhatia; Edward S Knock; Lucy Okell; Hannah C Slater; Azra C Ghani; Patrick G T Walker; Okefu Oyale Okoko; Thomas S Churcher Journal: Nat Med Date: 2020-08-07 Impact factor: 87.241
Authors: Kaja Abbas; Simon R Procter; Kevin van Zandvoort; Andrew Clark; Sebastian Funk; Tewodaj Mengistu; Dan Hogan; Emily Dansereau; Mark Jit; Stefan Flasche Journal: Lancet Glob Health Date: 2020-07-17 Impact factor: 26.763
Authors: Britta L Jewell; Edinah Mudimu; John Stover; Debra Ten Brink; Andrew N Phillips; Jennifer A Smith; Rowan Martin-Hughes; Yu Teng; Robert Glaubius; Severin Guy Mahiane; Loveleen Bansi-Matharu; Isaac Taramusi; Newton Chagoma; Michelle Morrison; Meg Doherty; Kimberly Marsh; Anna Bershteyn; Timothy B Hallett; Sherrie L Kelly Journal: Lancet HIV Date: 2020-08-06 Impact factor: 12.767
Authors: Daniel J Weiss; Amelia Bertozzi-Villa; Susan F Rumisha; Punam Amratia; Rohan Arambepola; Katherine E Battle; Ewan Cameron; Elisabeth Chestnutt; Harry S Gibson; Joseph Harris; Suzanne Keddie; Justin J Millar; Jennifer Rozier; Tasmin L Symons; Camilo Vargas-Ruiz; Simon I Hay; David L Smith; Pedro L Alonso; Abdisalan M Noor; Samir Bhatt; Peter W Gething Journal: Lancet Infect Dis Date: 2020-09-21 Impact factor: 25.071
Authors: Pascalina Chanda-Kapata; Francine Ntoumi; Nathan Kapata; Patrick Lungu; Luchenga Adam Mucheleng'anga; Jeremiah Chakaya; John Tembo; Cordelia Himwaze; Rashid Ansumana; Danny Asogun; Sayoki Mfinanga; Peter Nyasulu; Peter Mwaba; Dorothy Yeboah-Manu; Alimuddin Zumla; Jean B Nachega Journal: Int J Infect Dis Date: 2022-03-25 Impact factor: 12.074